LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The Lancet（2022）
摘要
Eli Lilly and Company.
更多查看译文
关键词
glucagon receptor agonist,novel triple gip,diabetes,double-blind,placebo-controlled,multiple-ascending
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要